[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.194.83. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,080
Citations 0
Clinical Trials Update
May 23/30, 2017

Therapies That Target PCSK9 Effective at Reducing LDL Cholesterol

JAMA. 2017;317(20):2054. doi:10.1001/jama.2017.5656

In a trial published recently in the New England Journal of Medicine (NEJM), evolocumab, a monoclonal antibody that inhibits circulating PCSK9 (proprotein convertase subtilisin-kexin type 9) by preventing it from binding to the low-density lipoprotein (LDL) receptor, was found to reduce LDL cholesterol and cardiovascular risk in patients with elevated cholesterol despite high-intensity statin therapy.

×